1Anderson F A Jr,Spencer FA.Risk factors for venous thromboembolism.Circulation.2003,107(23 s1):I9.
2Kearon C.Natural history of venous thromboembolism.Circulation,2003,107(23 s 1):I22.
3Lassen M R,Laux V.Emergence of new oral antithrombotics:a critical appraisal of their clinical potential.Vasc Health Risk Manag,2008,4(6):1373.
4Hirsh J,O'Donnell M,Eikelboom J W.Beyond unfractionated heparin and warfarin:current and future advances.Circulation,2007,116 (5):552.
5Spyropoulos A C.Managing oral anticoagulation requires expert experience and clinical evidence.J Thromb Thrombolysis,2006,21 (1):91.
6Harenberg J,Wehling M.Current and future prospects for anticoagulant therapy:inhibitors of factor Xa and factor Ⅱa.Semin Thromb Hemost,2008,34(1):39.
7Mann K G,Brummel K,Butenas S.What is all that thrombin for J Thromb Hacmost,2003,1 (7):1504.
8Gulseth M P,Michaud J,Nutescu E A.Rivaroxaban:an oral direct inhibitor of factor Xa.Am J Health-Syst Pharm,2008,65:1520.
9Graff J,von Hentig N,Misselwitz F,et al.Effects of the Oral,Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity.J Clin Pharmacol,2007,47:1398.
10Kubitza D,Becka M,Zuehlsdorf M,et al.Body weight has limited influence on the safety and tolerability,pharmacokinetics,or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.J Clin Pharmacol,2007,47:218.
